Fig. 1 · Structure

Cat. No.: A10844
CAS No.: 65666-07-1
Formula: C₂₅H₂₂O₁₀
Mol. Weight: 482.4

Documents & Downloads

Silymarin (Silybin B)

Name: Silymarin (Silybin B)
Brand: Adooq Bioscience
SKU: A10844
Availability: InStock

Cat. No. A10844 CAS 65666-07-1

Silymarin (Silibinin B) inhibits chemically induced urinary bladder tumor growth and progression possibly by inhibiting cell proliferation and enhancing apoptosis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vitro Studies

Silymarin (Silybin B) was tested in HTB9 cells by treatment in medium. Treatment at 60 µM for 48 h produced 40% growth inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Growth Inhibition in HTB9 Cells

Cell-based study · HTB9 Cells [1]

HTB9 cells treated with Silymarin (Silybin B) in medium at 60 µM for 48 h showed 40% growth inhibition.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
% growth inhibition	% growth inhibition 60 µM, 48 h: 40%	[1]

Literature-Reported Treatment Conditions

Treatment concentration: 60 µM
Exposure duration: 48 h
Method: in medium
Vehicle: DMSO

Methods and source locations

Compound reported in the paper: Silymarin (Silybin B); Compound label in the paper: Silybin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell Culture, Treatment and Reagents (S5, S6); Table 4 (T4.h1, T4.h2, T4.h3, T4.r1, T4.r6)

% growth inhibition: % growth inhibition; comparator: DMSO — Table 4 (T4.h1, T4.h2, T4.h3, T4.r6)

In Vivo Studies

Silymarin (Silybin B) was administered intragastrically to male SV129 mice receiving cisplatin. Blood urea nitrogen levels were significantly decreased in the silybin group compared with the cisplatin group. Silybin protected against cisplatin-induced AKI in WT mice but was unable to protect SIRT3 KO mice. [2]

Renal Outcomes in Cisplatin-Treated Mice

Animal study · Male SV129 mice were treated with vehicle and cisplatin with or without silybin (n = 6). [2]

The mice were pretreated with 200 mg/kg silybin per day by intragastric administration for 7 days before and 3 days after cisplatin injection. The blood urea nitrogen level was significantly decreased in the silybin group compared with the cisplatin group. Silybin was unable to protect against cisplatin-induced AKI in the SIRT3 KO mice, whereas it had a protective effect in the WT mice.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
blood urea nitrogen (BUN) levels of mice 72 h after cisplatin injection	Reported result 200 mg/kg silybin per day by intragastric administration for 7 days before and 3 days after cisplatin injection: The blood urea nitrogen level was significantly decreased in the silybin group compared with the cisplatin group. Silybin was unable to protect against cisplatin-induced AKI in the SIRT3 KO mice, whereas it had a protective effect in the WT mice.	[2]

Conditions shared by the study groups

Route: intragastric administration
Treatment course: per day by intragastric administration for 7 days before and 3 days after cisplatin injection

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Silymarin (Silybin B) 200 mg/kg	cisplatin group	200 mg/kg silybin per day by intragastric administration for 7 days before and 3 days after cisplatin injection: The blood urea nitrogen level was significantly decreased in the silybin group compared with the cisplatin group. Silybin was unable to protect against cisplatin-induced AKI in the SIRT3 KO mice, whereas it had a protective effect in the WT mice.	[2]

Silymarin (Silybin B) 200 mg/kg: Model: Male SV129 mice were treated with vehicle and cisplatin with or without silybin (n = 6).; Reported limits: Not stated in the sentences used: vehicle.

Methods and source locations

Compound reported in the paper: Silymarin (Silybin B); Compound label in the paper: Silybin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Mice and AKI Model (S4); Results > Silybin Protects against Cisplatin-induced AKI (S48, S51); Results > Silybin Increases SIRT3 Expression to Protect against Cisplatin-induced AKI (S72); FIGURE 1 legend (S93, S94)

blood urea nitrogen (BUN) levels of mice 72 h after cisplatin injection: blood urea nitrogen (BUN) levels of mice 72 h after cisplatin injection; comparator: cisplatin group — Materials and Methods > Mice and AKI Model (S4); Results > Silybin Protects against Cisplatin-induced AKI (S51); Results > Silybin Increases SIRT3 Expression to Protect against Cisplatin-induced AKI (S72); FIGURE 1 legend (S94)

Silymarin (Silybin B) 200 mg/kg · Materials and Methods > Mice and AKI Model (S4); Results > Silybin Protects against Cisplatin-induced AKI (S51); Results > Silybin Increases SIRT3 Expression to Protect against Cisplatin-induced AKI (S72)

Specifications

Manufacturer	Adooq Bioscience
CAS Number	65666-07-1
Formula	C₂₅H₂₂O₁₀
Molecular Weight	482.4
Synonyms	Silybin B; Silibinin B
SMILES	COc1cc([C@@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@H]2CO)ccc1O

Storage & Solubility

In Vitro Solubility

Reported Solubility

Solvent	Reported Solubility
DMSO	Warmed: 93 mg/mL (192.76 mM)
Water	Insoluble
Ethanol	1 mg/mL (2.07 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

[1] Agarwal C, Wadhwa R, Deep G, et al. Anti-cancer efficacy of silybin derivatives -- a structure-activity relationship. PLoS One (2013). PMID: 23555889 DOI: 10.1371/journal.pone.0060074 Source material
[2] Li Y, Ye Z, Lai W, et al. Activation of Sirtuin 3 by Silybin Attenuates Mitochondrial Dysfunction in Cisplatin-induced Acute Kidney Injury. Front Pharmacol (2017). PMID: 28424621 DOI: 10.3389/fphar.2017.00178 Source material

Documents & Downloads

Silymarin (Silybin B)

Select a Size

Package Sizes

DMSO Solution